Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-17.57 Insider Own81.62% Shs Outstand85.51M Perf Week-3.44%
Market Cap911.54M Forward P/E- EPS next Y- Insider Trans-0.09% Shs Float15.71M Perf Month-18.63%
Income-44.24M PEG- EPS next Q- Inst Own0.96% Short Float1.29% Perf Quarter-40.15%
Sales0.00M P/S- EPS this Y- Inst Trans-1.38% Short Ratio3.27 Perf Half Y-58.83%
Book/sh-11.77 P/B- EPS next Y- ROA-215.90% Short Interest0.20M Perf Year103.63%
Cash/sh0.03 P/C408.76 EPS next 5Y- ROE-269.01% 52W Range4.35 - 30.40 Perf YTD-58.51%
Dividend Est.- P/FCF- EPS past 5Y48.84% ROI-1257.95% 52W High-64.93% Beta2.05
Dividend TTM- Quick Ratio2.88 Sales past 5Y- Gross Margin- 52W Low145.06% ATR (14)0.99
Dividend Ex-DateSep 21, 2022 Current Ratio2.88 EPS Y/Y TTM-411.66% Oper. Margin0.00% RSI (14)38.62 Volatility5.65% 10.35%
Employees- Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom2.00 Target Price45.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q73.25% Payout- Rel Volume1.38 Prev Close10.84
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 09 AMC Avg Volume62.18K Price10.66
SMA20-4.03% SMA50-22.15% SMA200-27.52% Trades Volume85,965 Change-1.66%
Date Action Analyst Rating Change Price Target Change
Apr-29-21Resumed Stephens Overweight $18 → $19
Feb-10-21Initiated Piper Sandler Overweight $15
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Jun-18-24 04:05PM
May-30-24 04:05PM
May-28-24 04:05PM
May-09-24 04:10PM
Mar-28-24 05:32AM
06:32AM Loading…
Mar-26-24 06:32AM
Mar-21-24 07:00AM
Dec-15-23 09:04AM
Nov-13-23 07:00AM
Oct-30-23 12:00PM
Aug-23-23 12:36PM
Apr-03-23 09:01AM
Mar-29-23 10:13AM
Feb-28-23 08:00AM
07:00AM Loading…
Dec-27-22 07:00AM
Nov-16-22 05:05AM
Sep-19-22 09:43AM
Sep-01-22 04:05PM
Aug-25-22 08:00AM
Aug-23-22 07:11AM
Aug-19-22 08:00AM
Aug-15-22 04:05PM
Aug-11-22 06:00AM
Aug-10-22 12:46PM
Aug-03-22 08:00AM
Aug-01-22 08:30AM
Jul-22-22 12:21PM
Jul-19-22 08:00AM
09:40AM Loading…
Jul-14-22 09:40AM
Jul-06-22 08:00AM
Jun-29-22 08:00AM
Jun-28-22 09:40AM
May-26-22 11:03AM
May-23-22 09:57AM
May-09-22 08:30AM
Apr-08-22 09:57AM
Mar-31-22 08:00AM
Mar-15-22 05:00PM
Feb-17-22 08:00AM
Feb-03-22 05:38PM
Jan-25-22 08:00AM
Jan-12-22 12:00PM
Dec-20-21 07:51PM
Dec-11-21 11:59AM
Nov-22-21 08:00AM
Nov-12-21 09:54AM
Oct-29-21 08:00AM
Oct-28-21 03:05PM
Oct-13-21 04:05PM
Sep-28-21 04:01PM
Sep-24-21 08:00AM
Sep-17-21 07:06AM
Sep-15-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 08:00AM
Aug-05-21 10:55AM
Jul-29-21 03:05PM
Jul-22-21 08:00AM
Jul-19-21 04:01PM
Jul-14-21 08:00AM
Jul-06-21 08:00AM
Jul-01-21 08:00AM
Jun-28-21 08:45AM
Jun-21-21 06:00AM
Jun-10-21 08:00AM
May-20-21 02:57AM
May-18-21 08:00AM
May-13-21 08:00AM
May-06-21 12:19PM
May-05-21 12:29PM
Apr-28-21 08:00AM
Apr-21-21 11:43AM
Apr-19-21 08:00AM
Apr-12-21 08:00AM
Apr-07-21 04:05PM
Mar-21-21 04:20AM
Mar-04-21 08:00AM
Feb-18-21 08:00AM
Feb-11-21 04:01PM
Feb-10-21 10:05AM
Feb-03-21 08:00AM
Jan-29-21 04:01PM
Jan-27-21 08:00AM
Jan-26-21 04:04PM
Jan-20-21 08:00AM
Jan-19-21 11:46PM
Jan-15-21 08:00AM
Dec-15-20 10:28PM
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
USMAN NASSIMDirectorMay 01 '24Option Exercise6.9320,000138,60021,636May 02 06:19 PM
USMAN NASSIMDirectorMay 01 '24Sale14.1320,000282,5771,636May 02 06:19 PM
USMAN NASSIMDirectorApr 01 '24Option Exercise6.9320,000138,60021,636Apr 03 04:01 PM
USMAN NASSIMDirectorApr 01 '24Sale16.1520,000323,0001,636Apr 03 04:01 PM
USMAN NASSIMDirectorMar 15 '24Option Exercise6.9320,000138,60021,636Mar 19 04:47 PM
USMAN NASSIMDirectorMar 15 '24Sale17.2620,000345,2001,636Mar 19 04:47 PM